Sclerosis
Welcome,         Profile    Billing    Logout  
 125 Companies   183 Products   183 Products   133 Mechanisms of Action   1 Trial   2306 News 


«12...678910111213141516...4041»
  • ||||||||||  Avonex (recombinant IFN-β-1a) / Biogen
    Trial completion, Trial initiation date, Trial primary completion date, HEOR:  Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (clinicaltrials.gov) -  Oct 21, 2015   
    P=N/A,  N=100, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Nov 2010 --> Dec 2012 | Trial primary completion date: Sep 2015 --> Sep 2014
  • ||||||||||  Trial completion:  Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) -  Oct 17, 2015   
    P=N/A,  N=52, Completed, 
    Active, not recruiting --> Completed | Initiation date: Nov 2010 --> Dec 2012 | Trial primary completion date: Sep 2015 --> Sep 2014 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial primary completion date:  Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (clinicaltrials.gov) -  Oct 15, 2015   
    P4,  N=150, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Sep 2015
  • ||||||||||  Trial termination, Trial primary completion date:  Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS (clinicaltrials.gov) -  Oct 3, 2015   
    P2,  N=12, Terminated, 
    Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> May 2015; 12 SCI volunteers completed the study. As the data analysis was negative, the decision was made not to proceed with MS recruitment.
  • ||||||||||  Trial termination:  RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) -  Sep 28, 2015   
    P3,  N=74, Terminated, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; in the absence of benefits and because of a statistically significant excess mortality in the group of patients receiving active stimulation.
  • ||||||||||  Enrollment closed:  Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients (clinicaltrials.gov) -  Sep 25, 2015   
    P=N/A,  N=400, Active, not recruiting, 
    Active, not recruiting --> Terminated; in the absence of benefits and because of a statistically significant excess mortality in the group of patients receiving active stimulation. Recruiting --> Active, not recruiting
  • ||||||||||  Rebif (human IFN-β-1a) / EMD Serono
    Trial primary completion date:  Rebif® Rebidose® Versus Rebiject II® Ease-of-Use (clinicaltrials.gov) -  Sep 25, 2015   
    P4,  N=90, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Apr 2016
  • ||||||||||  Trial primary completion date:  Longitudinal Study of Outcomes Measures in ALS Trials (clinicaltrials.gov) -  Sep 25, 2015   
    P=N/A,  N=100, Active, not recruiting, 
    Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Dec 2014 --> Jun 2015
  • ||||||||||  Biomarker, Trial primary completion date:  A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers (clinicaltrials.gov) -  Sep 25, 2015   
    P=N/A,  N=250, Recruiting, 
    Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Trial completion:  Gilenya in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Sep 25, 2015   
    P2a,  N=30, Completed, 
    Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Trial primary completion date:  Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension (clinicaltrials.gov) -  Sep 24, 2015   
    P=N/A,  N=30, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Dec 2015
  • ||||||||||  sirolimus / Generic mfg.
    Trial primary completion date:  Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream (clinicaltrials.gov) -  Sep 24, 2015   
    P1,  N=15, Recruiting, 
    Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Sep 2016
  • ||||||||||  Enrollment closed, Trial primary completion date:  Detecting and Addressing Preclinical Disability (clinicaltrials.gov) -  Sep 24, 2015   
    P=N/A,  N=150, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016
  • ||||||||||  Trial primary completion date:  Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program (clinicaltrials.gov) -  Sep 23, 2015   
    P=N/A,  N=300, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jun 2016 Trial primary completion date: Dec 2014 --> Dec 2025
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) -  Sep 22, 2015   
    P=N/A,  N=12, Completed, 
    Trial primary completion date: Aug 2014 --> Aug 2018 Recruiting --> Completed | N=34 --> 12 | Trial primary completion date: Dec 2015 --> Sep 2015
  • ||||||||||  Enrollment status, Enrollment change:  Gastroesophageal Reflux Treatment in Scleroderma (clinicaltrials.gov) -  Sep 21, 2015   
    P3,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting Enrolling by invitation --> Recruiting | N=250 --> 80
  • ||||||||||  phenytoin / Generic mfg.
    Trial completion:  Neuroprotection With Phenytoin in Optic Neuritis (clinicaltrials.gov) -  Sep 10, 2015   
    P2,  N=92, Completed, 
    Enrolling by invitation --> Recruiting | N=250 --> 80 Recruiting --> Completed
  • ||||||||||  Enrollment closed, Trial primary completion date:  RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) -  Sep 8, 2015   
    P3,  N=74, Active, not recruiting, 
    Active, not recruiting --> Completed Suspended --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Nov 2015
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date, MRI:  Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Sep 2, 2015   
    P=N/A,  N=0, Withdrawn, 
    Initiation date: Apr 2013 --> Jul 2013 | Trial primary completion date: Apr 2014 --> Jan 2016 N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Apr 2015
  • ||||||||||  Enrollment closed, Trial primary completion date:  Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Sep 2, 2015   
    P=N/A,  N=60, Active, not recruiting, 
    N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
  • ||||||||||  oxcarbazepine / Generic mfg.
    Enrollment open, Trial initiation date:  PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) -  Aug 24, 2015   
    P2,  N=60, Recruiting, 
    Active, not recruiting --> Suspended | Trial primary completion date: Oct 2014 --> Jul 2014 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Oct 2014